Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBIT (2023 - 2026)

Rallybio's EBIT history spans 3 years, with the latest figure at -$6.4 million for Q4 2025.

  • On a quarterly basis, EBIT rose 44.76% to -$6.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$33.1 million, a 45.35% increase, with the full-year FY2025 number at -$33.1 million, up 45.35% from a year prior.
  • EBIT hit -$6.4 million in Q4 2025 for Rallybio, up from -$6.9 million in the prior quarter.
  • Over the last five years, EBIT for RLYB hit a ceiling of -$6.4 million in Q4 2025 and a floor of -$21.1 million in Q4 2023.
  • Historically, EBIT has averaged -$14.4 million across 3 years, with a median of -$14.6 million in 2024.
  • Biggest five-year swings in EBIT: decreased 7.69% in 2024 and later skyrocketed 51.13% in 2025.
  • Tracing RLYB's EBIT over 3 years: stood at -$21.1 million in 2023, then skyrocketed by 45.02% to -$11.6 million in 2024, then soared by 44.76% to -$6.4 million in 2025.
  • Business Quant data shows EBIT for RLYB at -$6.4 million in Q4 2025, -$6.9 million in Q3 2025, and -$10.1 million in Q2 2025.